Bravura Solutions Ltd. (AU000000BVS9)
XSTU 
NASDAQ (NGS) Primary XSTU Summary
AU000000BVS9 Chart
Are Investors Undervaluing Bioventus (BVS) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bioventus Highlights PNS, PRP Growth as Cash Flow Improves and Debt Falls
Bioventus NASDAQ: BVS executives outlined the company's portfolio strategy, growth priorities and capital allocation plans during a Goldman Sachs event hosted by Jenny Rabinowitz, an analyst covering U.S. medtech and healthcare IT.
Bioventus Inc. (BVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Bioventus Inc. (BVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Bravura Solutions Ltd. (AU000000BVS9) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Bravura Solutions Ltd. ever had a stock split?
Bravura Solutions Ltd. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Robert E. Claypoole CEO | XSTU Exchange | US09075A1088 ISIN |
| US Country | 930 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Bioventus Inc. is a pioneering medical device company that places a strong emphasis on innovating and providing treatments aimed at enhancing the body's intrinsic healing mechanisms. Operating both in the United States and internationally, the company has carved a niche for itself in the medical device industry by offering a wide range of products designed for pain management, surgical solutions, and restorative therapies. With its foundation in 2011 and headquarters in Durham, North Carolina, Bioventus stands as a beacon of advancement in leveraging medical technology to improve patient outcomes.
Products and Services
Pain Treatments: Bioventus' portfolio addresses non-surgical pain through injection therapies and peripheral nerve stimulation products. Key offerings include:
- Durolane: A treatment for knee osteoarthritis providing pain relief.
- GELSYN-3: A series of injections for knee osteoarthritis pain management.
- SUPARTZ: An injectable solution for knee osteoarthritis.
- Stimrouter: A device aimed at treating chronic peripheral pain.
Surgical Solutions: The company provides surgeons with innovative tools and biomaterials for bone and soft tissue procedures, featuring:
- Bone Graft Substitutes: Products like Osteoamp, Exponent matrix, Purebone, Signafuse bone graft, Interfuse bone graft, Osteomatrix+ synthetic bone graft, designed to stimulate bone healing.
- Ultrasonic Products: High-precision devices such as nexus ultrasonic surgical system, bonescalpel surgical solution, SonaStar, and SonicOne ultrasonic cleansing and debridement system for surgeries, including minimally invasive procedures.
- Extractor: A tool for autologous cell and bone marrow extraction to aid in bone healing.
- Reficio Bone Matrix: A novel bone graft substitute.
Restorative Therapies: Bioventus also addresses neurologic and musculoskeletal recovery, offering devices that aid in rehabilitation from strokes, multiple sclerosis, or central nervous system disorders. Products include:
- Exogen: A bone healing system.
- L300 GO: A system designed to improve foot drop conditions caused by central nervous system disorders.
- H200 Rehabilitation System: A solution to aid in regaining hand function.
- Vector: A body weight support system for gait and balance training.
- Bioness Integrated Therapy System: Offers comprehensive solutions for neurorehabilitation.
The company is also developing the Talisman Pulse Generator and Receiver, a potential breakthrough for peripheral nerve stimulation, showcasing Bioventus' commitment to ongoing innovation and improvement in the field of medical devices.
